European regulators recommend rejection of Merck’s Covid-19 drug molnupiravir

2023-02-24

临床3期紧急使用授权临床结果

European regulators recommended the EMA reject Merck’s Covid antiviral, saying that there’s not enough evidence it works in patients. Merck and partner Ridgeback Biotherapeutics announced the CHMP’s decision on Friday. The committee refused to recommend the approval of Lagevrio, also known as molnupiravir, by initially stating that the review has been ongoing for more than a year. The committee had supported decisions from member states starting in November 2021, if they wanted to consider early use of molnupiravir before any potential approval. Since then, the committee said that molnupiravir’s clinical benefit in adults with Covid-19 who are not on supplemental oxygen and at increased risk of developing severe Covid-19 “could not be demonstrated.” The CHMP said Merck submitted results of a study investigating the antiviral in more than 1,400 non-hospitalized and unvaccinated adults with “at least one underlying condition putting them at risk of severe Covid-19.” CHMP added: In a statement to Endpoints News , Merck said it believes “the CHMP’s recommendation does not reflect the compelling data” from its Phase III MOVe-OUT trial, the one that Merck used to obtain FDA emergency use authorization back in 2021. Merck added that it and Ridgeback are going to appeal the decision and request a re-examination of the CHMP’s opinion. This is the newest twist for molnupiravir after the FDA axed the requirement that patients test positive for Covid-19 in order to be prescribed either Lagevrio or Paxlovid earlier this month. The FDA has not been Lagevrio’s biggest supporter, after an FDA adcomm voted 13-10 to approve emergency authorization in 2021, despite concerns of the drug’s mechanism of action — and only showing 30% effectiveness in preventing hospitalizations and deaths, down from 50% in an interim analysis. FDA also said last summer that it would not allow Lagevrio to be prescribed by state-licensed pharmacists — even while allowing those same pharmacists to prescribe Paxlovid. Despite the recommendation for Lagevrio, the committee posted a handful of positive decisions from its monthly meeting this week. Those include Incyte’s non-segmental vitiligo treatment Opzelura and an extension for Regeneron’s Libtayo — this time comboed with chemotherapy for PD-L1 positive NSCLC PD-L1 positive NSCLC. Another positive recommendation went to Italian pharma Chiesi and partner Protalix BioTherapeutics’ candidate PRX-102, also known as Elfabrio, to treat Fabry disease.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构